Export of guanosine 3',5'-cyclic monophosphate (cGMP) from human erythrocytes characterized by inside-out membrane vesicles

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 56, Issue 4, 1996, Pages 289-293

  Sager, G ^a   Orbo A ^b   Pettersen, R H ^a   Kjorstad K E ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

ATP; cGMP; erythrocytes; inside out vesicles; transport

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLIC GMP;

ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; DIFFUSION; ERYTHROCYTE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MEMBRANE BINDING; MEMBRANE VESICLE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0029930665     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365519609090579     Document Type: Article

References (27)

1. Broadus AE, Hardman JG, Kaminsky NI, Ball JH, Sutherland EW, Liddie GW. Extracellular cyclic nucleotides. Ann NY Acad Sci 1971; 185: 50-65.
2. Murad F, Pak CYC. Urinary excretion of adenosine 3′,5′-monophosphate and guanosine 3′,5′-monophosphate. N Engl J Med 1972; 286: 1382-7.
3. Guthrie D, Isah H, Latner AL, Turner GA. Urine cyclic GMP: a possible biochemical marker for cancer. IRCS Med Sci 1979; 7: 209.
4. Chawla RK, Shlaer SM, Lawson DH, et al. Elevated plasma and urinary guanosine 3′:5′-monophosphate and increased production rate in patients with neoplastic diseases. Cancer Res 1980; 40: 3915-20.
5. Hunt NH, Smith B, Pembrey R. Cyclic nucleotide excretion in human malignancies. Clin Sci 1980; 58: 463-7.
6. Duttagupta C, Romney SL, Palan PR, Slagle NS. Urinary cyclic nucleotides and the cytopathology of human uterine cervical dysplasias. Cancer Res 1982; 42: 2938-43.
7. Turner GA, Ellis RD, Guthrie D, et al. Urine cyclic nucleotide concentrations in cancer and other conditions; cyclic GMP: a potential marker for cancer treatment. J Clin Pathol 1982; 35: 800-6.
8. Luesley DM, Blackledge GR, Chan KK, Newton JR. Random urinary cyclic 3′,5′ guanosine monophosphate in epithelial ovarian cancer: relation to other prognostic variables and to survival. Br J Obstet Gynaecol 1986; 93(4): 380-5.
9. Luesley DM, Chan KK, Newton JR, Blackledge GR. Serial urinary cyclic guanosine monophosphate measurements in the assessment of response to treatment in epithelial ovarian cancer. Br J Obstet Gynaecol 1987; 94(5): 461-6.
10. Vorderwinkler KP, Artner-Dworzak E, Jakob G, et al. Release of cyclic guanosine monophosphate evaluated as a diagnostic tool in cardiac diseases. Clin Chem 1991; 37(2): 186-90.
11. Abraham WT, Hensen J, Kim JK, et al. Atrial natriuretic peptide and urinary cyclic guanosine monophosphate in patients with chronic heart failure. J Am Soc Nephrol 1992; 2(12): 1697-703.
12. Zheng X, Ma SJ, Zhang TH, Chen SC. Plasma levels of cyclic nucleotides in chronic congestive heart failure and their clinical implication. Int J Cardiol 1993; 40(1): 7-15.
13. Jakob G, Mair J, Vorderwinkler KP, et al. Clinical significance of urinary cyclic guanosine monophosphate in diagnosis of heart failure. Clin Chem 1994; 40(1): 96-100.
14. Hamet P, Pang SC, Tremblay J. Atrial natriuretic factor-induced egression of cyclic guanosine 3′:5′-monophosphate in cultured vascular smooth muscle and endothelial cells. J Biol Chem 1989; 264: 12364-9.
15. Kapoor CL, Krishna G. Hormone-induced cyclic guanosine monophosphate secretion from guinea pig pancreatic lobules. Science 1977; 196: 1003-5.
16. Tjörnhammar M-L, Lazaridis G, Bartfai T. Cyclic GMP efflux from liver slices. J Biol Chem 1983; 258: 6882-6.
17. Ørbo A, Jaeger R, Sager G. Effect of serum and cell density on transmembrane distribution of cAMP and cGMP in transformed (C4-I) and nontransformed (WI-38) human cells. Int J Cancer 1993; 55: 957-62.
18. Steck TL, Weinstein RS, Straus JH, Wallach DFH. Inside-out cell membrane vesicles: preparation and purification. Science 1970; 168: 255-7.
19. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt Biochem 1976; 72: 248-54.
20. Billiar TR, Curran RD, Harbrecht BG, et al. Association between synthesis and release of cGMP and nitric oxide biosynthesis by hepatocytes. Am J Physiol 1992; 262: C1077-82.
21. O'Dea RF, Gagnon C, Zatz M. Regulation of guanosine 3′,5′ cyclic monophosphate in the rat pineal and posterior pituitary glands. J Neurochem 1978; 31: 733-8.
22. Tjörnhammar M-L, Lazaridis G, Bartfai T. Efflux of cyclic guanosine 3′,5′-monophosphate from cerebellar slices stimulated by L-glutamate or high K+ or N-methyl-N′-nitro-N-nitrosguanidine. Neurosci Lett 1986; 68: 95-9.
23. Kondo T, Dale GL, Beutler E. Glutathione transport by inside-out vesicles from human erythrocytes. Proc Natl Acad Sci USA 1980; 77: 6359-62.
24. Kondo T, Dale GL, Beutler E. Studies on gluthathione transport utilizing inside-out vesicles prepared from human erythrocytes. Biochim Biophys Acta 1981; 645: 132-6.
25. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992; 8: 67-113.
26. Beavo J. Multiple phosphodiesterase isoenzymes - background, nomenclature and implications. In: Beavo J, Houslay MD, editors. Cyclic nucleotide phosphodiesterases: structure, regulation and drug action. Chichester: John Wiley, 1990: vol 2, 3-15.
27. Torphy TJ, Cieslinski LB. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle. Mol Pharmacol 1990; 37(2): 206-14.